Argenteuil, outside Paris in France, a prominent public hospital is now initiating a pilot project offering women to combine their mammography examination with osteoporosis screening in a single examination. The combined assessment of bone health is made possible by Sectra’s patented online service, Sectra OneScreen.

Breast cancer tumors often express vascular endothelial growth factor (VEGF)-A and a method of detection involving PET and the monoclonal antibody tracer Zr-89 bevacizumab is showing promise for the assessment of early to late stage primary malignancy, according to a study published May 7 in the Journal of Nuclear Medicine.

Data examining the outcomes of cancer screening decision aids designed to help improve doctor-patient communication and educate patients about the pros and cons of timing, frequency and methods of breast, cervical, colon and prostate cancer screening are variable and sparse, according to a study published in the May/June issue of CA: A Cancer Journal for Clinicians.

Digital mammography and film-screen mammography deliver comparable breast cancer detection performance, but computed radiography (CR) mammography was less likely by 21 percent to help detect breast cancer, according to a study published online May 14 in Radiology.

Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.

Sometimes we collectively need a wake up call. Mine came three years ago when a friend and industry colleague, an imaging sales executive, tragically passed away months before turning 40, after a heroic fight against colon cancer. He was a great guy – he took excellent care of himself, he was fit, he always had a smile on his face, and he adored his wife and two young kids.

Simultaneous PET/MR broke additional ground toward clinical use by showing technical success and potential clinical merit for FDG PET/MR detection of ischemic heart disease, according to a study published May 7 in Radiology.

The cancellation rate for MRI-guided breast biopsies due to nonvisualization of suspicious lesions detected with 3T MRI is 13 percent, which is similar to rates reported for lesions detected with 1.0 and 1.5T MRI, according to a study published in the May issue of Academic Radiology.